Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1703793-34-3
Formula :	C₂₆H₂₇FN₁₀
M.W :	498.56
SMILES Code :	N[C@@](C)(C1=CC=C(F)C=C1)C2=CN=C(N3CCN(C4=NC=NN5C4=CC(C6=CN(C)N=C6)=C5)CC3)N=C2
Synonyms :	BLU-285
MDL No. :	MFCD31544325
InChI Key :	DWYRIWUZIJHQKQ-SANMLTNESA-N
Pubchem ID :	118023034

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

PDGFRA D842V PDX cells	100 nM	24 h	Evaluate the effect of ML-7 and Avapritinib on the cytoskeleton	PMC10239357
GIST882	120 nM	120 h	Evaluate the effects of MK-1775 and avapritinib on three-dimensional spheroid growth. Results showed that combination treatment significantly reduced spheroid viability and volume.	PMC7934848
GIST-T1+D842V KITKO	103.8 nM	72 h	Evaluate the effects of MK-1775 and avapritinib on cell cycle and apoptosis. Results showed that MK-1775 induced G0/G1-phase arrest, while avapritinib induced G2 arrest. Combination treatment significantly increased the subG1 population, indicating increased apoptosis.	PMC7934848
GIST-T1+Cas9	19.6 Nm	72 h	Evaluate the effects of MK-1775 and avapritinib on cell cycle and apoptosis. Results showed that MK-1775 induced G2 phase cell cycle arrest, while avapritinib induced G0/G1-phase arrest. Combination treatment significantly increased the subG1 population, indicating increased apoptosis.	PMC7934848
GIST T1 cells	100 nM	24 or 48 h	Evaluate the effect of Avapritinib on GIST T1 cell viability and MYLK upregulation	PMC10239357
S1-M1-80	0.1 – 1.0 μM	72 h	avapritinib reversed ABCG2-mediated mitoxantrone resistance	PMC6620786
KB-3-1	0.1 – 1.0 μM	72 h	avapritinib resensitized ABCB1-overexpressing KB-V1 cancer cells to paclitaxel at non-toxic concentrations	PMC6620786
HEK293	20 μM		To evaluate the effect of avapritinib on the drug transport function of ABCB1 and ABCG2	PMC6620786

C.B17 SCID mice	GIST-T1+Cas9 and GIST-T1+D842V KITKO xenograft models	Oral	10 mg/kg	Daily administration until tumor volume exceeded 10% of body weight or animals demonstrated distress or weight loss greater than 10%.	Evaluate the effects of MK-1775 and avapritinib combination therapy on tumor growth and survival. Results showed that combination treatment significantly inhibited tumor growth and induced tumor regression in the GIST-T1+D842V KITKO model. Combination treatment significantly prolonged survival.	PMC7934848
NSG mice	PDGFRA D842V-mutant GIST xenograft model	Oral gavage	3, 10 or 30 mg/kg	Once daily for 2 weeks	Evaluate the effect of Avapritinib alone or in combination with ML-7 on tumor volume and signaling pathways	PMC10239357
Mice	H3.3K27M/p53LOF/PDGFRAWT (KPP) model	Oral administration	30 mg/kg	15 consecutive days	Evaluation of the therapeutic effect of avapritinib on the KPP model showed that avapritinib significantly extended survival (median survival 18 days vs. 26 days, P=0.0023).	PMC10326601

{[proInfo.proName]}

CAS No.: 1703793-34-3

{[proInfo.proName]}

CAS No.: 1703793-34-3

Alternative Products

Product Details of Avapritinib

Safety of Avapritinib

Related Pathways of Avapritinib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03465722	GIST	Phase 3	Recruiting	April 2023	-
NCT03731260	Indolent Systemic Mastocytosis... More >> Smoldering Systemic Mastocytosis Less <<	Phase 2	Not yet recruiting	November 2023	-
NCT02508532	Gastrointestinal Stromal Tumor... More >>s (GIST)\|Other Relapsed or Refractory Solid Tumors Less <<	PHASE1	COMPLETED	2021-06-03	Scottsdale Healthcare Hospital... More >>s DBA HonorHealth, Scottsdale, Arizona, 85258, United States\|Sarcoma Oncology Center, Santa Monica, California, 90403, United States\|Sylvester Comprehensive Cancer Center, Miami, Florida, 33136, United States\|Cancer Treatment Centers of America, Atlanta, Georgia, 30256, United States\|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States\|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States\|Oregon Health and Science University, Portland, Oregon, 97239, United States\|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States\|MD Anderson Cancer Center, Houston, Texas, 77030, United States\|Leuven Cancer Institute University Hospitals Leuven, Leuven, 3000, Belgium\|Centre Leon Berard, Lyon, 69008, France\|Institut Gustave Roussy, Paris, 94805, France\|University of Duisburg-Essen, Essen, 45122, Germany\|Fondazione IRCCS - Istituto Nazinale dei Tumori, Milan, 20133, Italy\|Asan Medical Center, Seoul, 05505, Korea, Republic of\|Erasmus MC Cancer Institute, Rotterdam, 3015, Netherlands\|Centrum Onkologii-Instytut im. Marii Sk?odowskiej-Curie w Warszawie, Warsaw, 02-781, Poland\|Vall d' Hebron Institute of Oncology (VHIO), Barcelona, 08305, Spain\|Royal Marsden Hospital, London, SW3 6JJ, United Kingdom Less <<
NCT02561988	Aggressive Systemic Mastocytos... More >>is\|Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease\|Mast Cell Leukemia\|Relapsed or Refractory Myeloid Malignancies Less <<	PHASE1	COMPLETED	2023-01-19	Stanford Cancer Institute, Sta... More >>nford, California, 94305, United States\|University of Colorado Cancer Center, Denver, Colorado, 80045, United States\|Emory University, Atlanta, Georgia, 30322, United States\|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States\|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States\|Mount Sinai Hospital, New York, New York, 10029, United States\|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States\|MD Anderson Cancer Center, Houston, Texas, 77030, United States\|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States\|Beatson West of Scotland Cancer Centre, Glasgow, G12 0XL, United Kingdom\|Guy's Hospital, London, SE1 9RT, United Kingdom Less <<
NCT03580655	Advanced Systemic Mastocytosis... More >>\|Aggressive Systemic Mastocytosis\|Systemic Mastocytosis With an Associated Hematologic Neoplasm\|Mast Cell Leukemia Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2026-01-31	Stanford Cancer Institute, Sta... More >>nford, California, 94305, United States\|Rush University Medical Center, Chicago, Illinois, 60612, United States\|The University of Kansas Cancer Center, Westwood, Kansas, 66205, United States\|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States\|University of Michigan, Ann Arbor, Michigan, 48109, United States\|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States\|Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, United States\|Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States\|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States\|University of Texas, MD Anderson Cancer Center, Houston, Texas, 77030, United States\|Mays Cancer Center, San Antonio, Texas, 78229, United States\|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States\|Medizinische Universit?t Wien, Universit?tsklinik für Innere Medizin I, Klinische Abteilung für H?matologie und H?mostaseologie, Vienna, 1090, Austria\|St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada\|Odense University Hospital, Department of Haematology, Odense, DK-5000, Denmark\|H?pital Necker-Enfants Malades, Paris, 75015, France\|CHU Toulouse - H?pital Larrey, Toulouse, 31059, France\|Uniklinik RWTH Aachen, Klinik für H?matologie, Onkologie, H?mostaseologie und Stammzelltranslplantation, Aachen, 52074, Germany\|Universit?tsklinikum Hamburg-Eppendorf, Zentrum für Onkologie, Hamburg, 20246, Germany\|Universit?tsklinikum Leipzig, Medizinische Klinik und Poliklinik I - H?matologie und Zelltherapie, lnternistische Onkologie, H?mostaseologie, Leipzig, 04103, Germany\|Universit?tsmedizin Mannheim III. Medizinische Klinik, Mannheim, 68167, Germany\|Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München, Munich, 81675, Germany\|Azienda Ospedaliero-Universitaria Careggi, CRIMM - Centro di Ricerca ed Innovazione per le Malattie Mieloproliferative, Florence, 50134, Italy\|A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno, Salerno, 84131, Italy\|Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona, Verona, 37134, Italy\|University Medical Center Groningen (UMCG), Groningen, 9713 GZ, Netherlands\|Oslo University Hospital-Rikshospitalet, Hematology, Oslo, 0372, Norway\|Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdańsk, 80-214, Poland\|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroc?awiu, Klinice Hematologii, Nowotworów Krwi i Transplantacji Szpiku, Wroc?aw, 50-367, Poland\|lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo, Toledo, 45071, Spain\|Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, G12 0YN, United Kingdom\|Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital, London, SE1 9RT, United Kingdom Less <<
NCT04771520	Anatomic Stage IV Breast Cance... More >>r AJCC V8\|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8\|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8\|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC V8\|Locally Advanced Malignant Solid Neoplasm\|Locally Advanced Melanoma\|Locally Advanced Primary Malignant Central Nervous System Neoplasm\|Locally Advanced Sarcoma\|Metastatic Malignant Solid Neoplasm\|Metastatic Melanoma\|Metastatic Primary Malignant Central Nervous System Neoplasm\|Metastatic Sarcoma\|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8\|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8\|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC V8\|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8\|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC V8\|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC V8\|Prognostic Stage IIIC Breast Cancer AJCC V8\|Prognostic Stage IV Breast Cancer AJCC V8\|Stage IIIC Colorectal Cancer AJCC V8\|Stage IIIC Lung Cancer AJCC V8\|Stage IV Colorectal Cancer AJCC V8\|Stage IV Lung Cancer AJCC V8\|Stage IVA Colorectal Cancer AJCC V8\|Stage IVA Lung Cancer AJCC V8\|Stage IVB Colorectal Cancer AJCC V8\|Stage IVB Lung Cancer AJCC V8\|Stage IVC Colorectal Cancer AJCC V8 Less <<	PHASE2	RECRUITING	2025-02-03	M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less <<
NCT03862885	GIST		APPROVED_FOR_MARKETING	-	-
NCT06765915	AML, Adult	PHASE2	NOT_YET_RECRUITING	2028-02-01	Ruijin Hospital of Shanghai Ji... More >>aotong University, Shanghai, Shanghai, China Less <<
NCT04825574	Gastrointestinal Stromal Tumor... More >>s Less <<	PHASE4	COMPLETED	2023-11-23	Gustave Roussy Cancer Campus G... More >>rand Paris Institut de Cancerologie Gustave-Roussy, Villejuif, Val-de-Marne, 94800, France Less <<
NCT05821738	Core Binding Factor Acute Myel... More >>oid Leukemia\|KIT Mutation-Related Tumors Less <<	PHASE2	RECRUITING	2025-12-31	First Affiliated Hospital of S... More >>oochow University, Suzhou, Jiangsu, 215000, China Less <<
NCT04714086	Solid Tumors		NO_LONGER_AVAILABLE	-	-
NCT06748001	Mastocytosis, Systemic	PHASE4	RECRUITING	2027-12-31	Universitair Ziekenhuis Antwer... More >>pen (UZA), Edegem, 2650, Belgium\|Erasmus Medisch Centrum, Rotterdam, 3015, Netherlands\|Oslo University Hospital, Oslo, 0424, Norway Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.01mL 0.40mL 0.20mL	10.03mL 2.01mL 1.00mL	20.06mL 4.01mL 2.01mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed